US FDA

FDA distinguishes approved semaglutide products from compounded semaglutide risk

FDA describes approved semaglutide products and warns about dosing errors and quality concerns associated with compounded semaglutide products.

Primary source

1.
FDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products 2024.
Accessed 2026-06-08.
FDA distinguishes approved semaglutide products from compounded semaglutide products and describes dosing-error concerns.
2.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.